Literatur
- 1
Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S.
Diagnostic value of CEA, CA 15 - 3, CA 19 - 9, CYFRA 21 - 1, NSE and TSA assay in
pleural effusions.
Lung Cancer.
2001;
31
9-16
- 2
Barth Z, Thiele H, frenzel H, Kohler B.
Eine seltene Ursache für malignen Aszites - das Peritonealmesotheliom.
Dtsch Med Wochenschr.
2001;
126
778-782
- 3
Ebert W, Hoppe M, Muley T, Drings P.
Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA
21 - 1, TPA-TP, CEA and NSE.
Anticancer Res.
1997;
17
2875-2878
- 4
Fuhrmann C, Duche J C, Chouaid C, Abd Alsamad I, Atassi K, Monnet I, Tillement J P,
Housset B.
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural
malignancies.
Clin Biochem.
2000;
33
405-410
- 5
Marukawa M, Hiyama J, Shiota Y, Ono T, Sasaki N, Taniyama K, Mashiba H.
The usefulness of CYFRA 21 - 1 in diagnosing and monitoring malignant pleural mesothelioma.
Acta Med Okayama.
1998;
52
119-123
- 6
Nisman B, Barak V, Heching N, Kramer M, Reinus C, Lafair J.
Cytokeratin markers in malignant pleural mesothelioma.
Cancer Detect Prev.
1998;
22
416-421
- 7
Paganuzzi M, Onetto M, Marroni P, Filibert R, Tassara E, Parodi S, Felleti R.
Diagnostic value of CYFRA 21 - 1 tumor marker and CEA in pleural effusion due to
mesothelioma.
Chest.
2001;
119
1138-1142
- 8
Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A.
Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination
improve the results?.
Br J Cancer.
1995;
72
170-173
- 9
Schouwink H, Korse C M, Bonfrer J M, Hart A A, Baas P.
Prognostic value of serum tumuor markers CYFRA 21 - 1 and tissue polypeptide antigen
in malignant mesothelioma.
Lung Cancer.
1999;
25
25-32
Dr. med. Z. Barth
Prof. Dr. med. B. Kohler
Medizinische Klinik der Fürst-Stirum-Klinik Bruchsal
Gutleutstraße 1-14
76646 Bruchsal
